Search
for
Sort by
Research 31–60 of 340
- Mitigating GLP-1–Related Dermatologic Adverse Effects through Methylene Blue’s Antioxidant Action
- GLP-1 RAs and Skin Health: Exploring Dermatologic Side Effects and Therapeutic Interventions
- Exploring the hair loss risk in glucagon‐like peptide‐1 agonists: Emerging concerns and clinical implications
- GLP-1 Receptor Analogs: Evidence Linking to Effect on Metabolic and Reproductive Functions in Patients with PCOS and Obesity
- Glucagon-like peptide-1 receptor and proglucagon expression in mouse skin
- GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling
- Abstract 4142154: Risk of Suicide, Hair Loss, and Aspiration with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Pharmacovigilance Study from the FAERS database
- Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes
- The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe?
- Nonscarring Alopecia in Adults Treated With GLP ‐1s: A Propensity Score Matched TriNetX Cohort Study
- 74126 GLP-1RA Medications and Alopecia: Evaluating Risk Across Diabetic and Non-Diabetic Populations
- Metabolic syndrome – a new definition and management guidelines A joint position paper by the Polish Society of Hypertension, Polish Society for the Treatment of Obesity, Polish Lipid Association, Polish Association for Study of Liver, Polish Society of Family Medicine, Polish Society of Lifestyle Medicine, Division of Prevention and Epidemiology Polish Cardiac Society, “Club 30” Polish Cardiac Society, and Division of Metabolic and Bariatric Surgery Society of Polish Surgeons
- Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome
- Alopecia and Semaglutide: Connecting the Dots for Patient Safety
- Women with PCOS have a heightened risk of cardiometabolic and cardiovascular diseases: statement from the Experts Group on Inositol in Basic and Clinical Research and PCOS (EGOI-PCOS) and Italian Association of Hospital Cardiologists (ANMCO)
- Non-Hormonal Treatment Options for Regulation of Menstrual Cycle in Adolescents with PCOS
- Impact of Reducing Obesity in PCOS: Methods and Treatment Outcomes
- Dermatological adverse reactions and therapeutic potential of semaglutide, liraglutide and tirzepatide: Analysis of UK pharmacovigilance data and literature review
- Peptide Therapy in Aesthetic, Metabolic, and Endocrine Medicine
- THE VICIOUS CYCLE OF POLYCYSTIC OVARY SYNDROME AND BINGE EATING DISORDER: A REVIEW OF METABOLIC, PSYCHOLOGICAL, AND IATROGENIC PATHWAYS
- Management of Hirsutism and Acne in Women with Polycystic Ovary Syndrome: A Narrative Review of Current Evidence and Emerging Therapies
- Maternal obesity and the metabolic syndrome in reproductive health: assessing incretin-based interventions
- CURRENT THERAPEUTIC APPROACHES IN THE MANAGEMENT OF POLYCYSTIC OVARY SYNDROME
- INDIVIDUALIZED TREATMENT OF POLYCYSTIC OVARY SYNDROME: A MANIFESTATION-GUIDED PRACTICAL APPROACH
- Endocrinologia e Medicina Estética Ed. X
- Telogen Effluvium and Metabolic Stress in Modern Weight Loss Interventions: A Narrative Clinical Review
- Abstracts from the 2024 WDS Forum - virtual option
- Antidiabetic Management Strategies for Treatment of Polycystic Ovarian Syndrome
- Blockbuster Weight-Loss Drugs Not Tied to Suicidality, Studies Show
- Semaglutide and the Skin: An Overview of Current Evidence